CLAIMS

1. A multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79b, wherein the binding domain specific for CD79b comprises 3 heavy chain CDRs having the sequence given in SEQ ID NO: 88 for CDRH1, SEQ ID NO: 89 for CDRH2 and SEQ ID NO: 90 for CDRH3; and the binding domain specific for CD79b comprises 3 light chain CDRs having the sequence given in SEQ ID NO: 85 for CDRL1, SEQ ID NO: 86 for CDRL2 and SEQ ID NO: 87 for CDRL3 and wherein the binding domain specific for CD22 comprises 3 heavy chain CDR having the sequence given in SEQ ID NO: 138 for CDRH1, SEQ ID NO: 139 for CDRH2 and SEQ ID NO: 140 for CDRH3; and wherein the binding domain specific for CD22 comprises 3 light chain CDRs having the sequence given in SEQ ID NO: 135 for CDRL1, SEQ ID NO: 136 for CDRL2 and SEQ ID NO: 137 for CDRL3; wherein optionally the cysteine in SEQ ID NO: 139 is replaced by serine.
2. The multispecific molecule according to claim 1 wherein the binding domain or binding domains comprise an antibody variable region specific to the relevant antigen.
3. The multispecific molecule according to claim 1 or claim 2 wherein each binding domain comprises two antibody variable domains.
4. The multispecific molecule according to claim 3 wherein the two antibody variable domains are a VH/VL pair.
5. The multispecific molecule according to any one of claims 1 to 4, wherein the molecule is bispecific or trispecific.
6. The multispecific molecule according to any one of claims 1 to 5, wherein the molecule is a fusion protein.
7. The multispecific molecule according to any one of claims 1 to 4, wherein the molecule format is selected from diabody, scdiabody, triabody, tandem scFv, FabFv, Fab'Fv, FabdsFv, Fab-scFv, Fab-dsscFv, Fab-$(dsscFv)_2$ diFab, diFab', tribody, tandem scFv-Fc, scFv-Fc-scFv, scdiabody-Fc, scdiabody-CH3, Ig-scFv, scFv-Ig, V-Ig, Ig-V, Duobody and DVD-Ig.
8. The multispecific molecule according to any one of claims 1 to 7 wherein each binding domain is monospecific.
9. The multispecific molecule according to any one of claims 1 to 8 wherein the multispecific molecule comprises no more than one binding domain which is specific to CD22 and no more than one binding domain which is specific to CD79b.
10. The multispecific molecule according to any one of claims 1 to 9 wherein the binding domain which is specific to CD22 and the binding domain which is specific to CD79b are independently selected from a Fab, scFv, Fv, dsFv and dsscFv.

11. A multispecific molecule according to any one of claims 1 to 10 in which the binding domains are humanised.
12. A multispecific molecule according to any one of claims 1-11, which further comprises a binding domain specific to serum albumin, such as human serum albumin.
13. A composition comprising one or more multispecific molecule as defined in any one of claims 1 to 12.
14. A nucleotide sequence encoding a multispecific molecule as defined in any one of claims 1 to 12.
15. A vector comprising a nucleotide sequence defined in claim 14.